Lipiget

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lipiget

Lipiget is a highly effective lipid-lowering agent known for its specific mechanism of action in managing blood fat levels. It is a prescription drug used to address various forms of dyslipidemia.


Quick Facts: Atorvastatin

Property Description
Active ingredient Atorvastatin (INN)
Form Film-coated tablet
Pharmacological class HMG-CoA Reductase Inhibitor (Statin)
Common use Modifying the lipid profile
Origin Synthetic compound

Lipiget: A Statin and HMG-CoA Reductase Inhibitor

Lipiget is a synthetic, single-ingredient prescription drug that contains the active substance Atorvastatin. It belongs to the statin family of medications, which are formally designated as HMG-CoA reductase inhibitors. This classification indicates its unique role as a highly effective lipid-lowering agent, an action clinically recognized for its critical impact on cardiovascular risk reduction.

The drug's recognized status underscores its importance and efficacy in public health worldwide. The Atorvastatin active component is a chemically manufactured compound, ensuring a consistent and high standard of potency and action, distinguishing it as a reliable pharmacological product supported by extensive clinical experience.


What is Atorvastatin and Its Pharmaceutical Form?

The core component in Lipiget is the active ingredient Atorvastatin, which is administered as a film-coated tablet for simple and reliable oral administration. The drug's formulation ensures its systemic delivery into the body. The film-coated tablet is a practical and convenient oral dosage form, making Lipiget a suitable long-term option for adults managing their blood fat levels.

Lipiget is a single-ingredient product, containing only Atorvastatin and the necessary inert excipients that form the solid pharmaceutical base of the tablet. The consistent formulation and dosage form are key differentiating factors ensuring predictable absorption.


General Purpose of This Lipid-Lowering Agent

The general purpose of Lipiget is to effectively modify the lipid profile by targeting the primary pathway of cholesterol production in the liver. Its action involves the selective inhibition of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis.

This targeted action systematically leads to the reduction of low-density lipoprotein cholesterol (LDL-C), often called "bad" cholesterol, as well as triglycerides. The general benefit is that by lowering the concentration of these harmful fats, the medication helps in the management of dyslipidemia, which is a condition managed by this class of medication.

Regulatory References

  1. NIH/NLM Drug Information on Atorvastatin
  2. WHO Essential Medicines List (Atorvastatin entry)
  3. MedlinePlus Dyslipidemia Overview

What side effects are possible with Lipiget?

Possible Side Effects and Safety Information

Lipiget (Atorvastatin) safety profile is defined by official regulatory classifications, detailing effects across various body systems. Adverse reactions are grouped by frequency, based on clinical trial data and postmarketing reports. Reactions classified as most common often affect the upper respiratory or musculoskeletal systems, including nasopharyngitis, headache, joint pain (arthralgia), and diarrhea.


System-Organ Classes and Serious Reactions

The most significant documented effects involve the Musculoskeletal System and the Hepatobiliary System. Safety information emphasizes rare, but serious, adverse reactions, such as Rhabdomyolysis, a severe form of muscle breakdown, and reports of hepatic failure (liver failure)

. Increases in liver enzymes (transaminases) have been noted, typically appearing soon after treatment initiation and often being transient.


Safety Considerations and Constraints

The regulatory label specifies important constraints and population-specific safety notes. Lipiget is contraindicated in active liver disease, including persistent elevations in hepatic transaminase levels. It is also contraindicated during pregnancy and lactation due to the potential for fetal harm. Older age (65 years and above) and conditions like renal impairment are listed as predisposing factors that may increase the risk of myopathy. Furthermore, the risk of severe muscle effects is heightened by concomitant use with certain other drugs.

Overdose and Emergency Response

Overdose and when to seek help

The regulatory profile for Lipiget (Atorvastatin) overdose is defined by the necessary emergency response and specific monitoring requirements, rather than a unique set of documented symptoms.

Official Regulatory Statements on Overdose

Feature Regulatory Statement
Documented Presentations No specific symptoms or clinical signs resulting from acute overdosage are explicitly documented in the official regulatory sections.
Antidote Availability No specific treatment or antidote is available for Atorvastatin overdosage. Hemodialysis is not expected to be effective.
Required Emergency Action Immediate medical attention must be sought for the institution of symptomatic treatment and general supportive measures, as required.

Monitoring Requirements

In the event of an overdose, a medical facility must institute specific monitoring procedures, as mandated by the drug's prescribing information:

  • Monitoring of Liver function values (e.g., serum transaminases) is required.
  • Monitoring of serum Creatine Phosphokinase (CPK) values is required to assess for potential muscle toxicity.

When to Seek Urgent Help: Urgent medical help is necessary to institute the mandated symptomatic and supportive treatment and to perform the required laboratory monitoring, ensuring proper medical management and observation in a high-exposure scenario.

Therapeutic Uses of Lipiget

What Lipiget Treats: Main Uses and Benefits

Lipiget's active ingredient, atorvastatin, belongs to a class of medicines known as statins. As an adjunct to diet, its primary role is in managing dyslipidemias—conditions involving systemic imbalance of fats in the blood, especially when it involves elevated cholesterol levels. Its use is focused on managing the overall systemic burden associated with these lipid imbalances.

This symptomatic support contributes to easing the overall symptom burden by reducing the amount of cholesterol that may contribute to physiological strain. In a relevant clinical context, this supportive management may assist with reducing the risks associated with cardiovascular events, and supports general well-being during symptomatic phases related to cardiovascular health. It is commonly used for managing conditions characterized by periods of heightened symptoms where functional stability becomes affected within the cardiovascular system.

The medicine is relevant for easing symptoms linked to primary hypercholesterolemia, mixed dyslipidemia, and certain conditions involving elevated triglycerides or LDL-C. This approach helps patients cope more steadily with symptom fluctuations.

Quick Fact: Support for Systemic Imbalance

Regulatory References

  1. Atorvastatin: MedlinePlus Drug Information

Eligibility and Restrictions for Use

Lipiget (atorvastatin) eligibility is defined by official regulatory labeling, setting clear rules on which populations may be treated and which are formally excluded.

Contraindications (Must Not Use)

Use is absolutely prohibited (contraindicated) for patients with:

  • Active Liver Disease, including persistent, unexplained elevations of liver enzymes.
  • Known Hypersensitivity to atorvastatin or any component of the tablet.
  • Pregnancy and Lactation (Breastfeeding), as generally stated in the regulatory labels.

Age-Related Eligibility

Age Group Eligibility Status (Official Labeling)
Adults Approved for all labeled uses.
Children and Adolescents Approved only for patients 10 years of age and older with specific familial hypercholesterolemia.
Children under 10 Safety and efficacy have not been established for any indication.

Conditional Use and Risk Factors

Use requires careful consideration in populations with certain predisposing factors, such as renal impairment or uncontrolled hypothyroidism, as these are documented risk factors for muscle problems (myopathy/rhabdomyolysis) in the regulatory labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Lipiget (Atorvastatin) is primarily defined by the metabolism of the medicine and the risk of developing muscle-related side effects, such as myopathy or rhabdomyolysis.


Pharmacokinetic and Exposure-Modifying Interactions

Lipiget is metabolized by the enzyme CYP3A4 and transported by proteins like OATP1B1 and P-glycoprotein. Interactions with other medicines often center on these pathways, resulting in changes to Lipiget levels in the blood.

Mechanism/Category Examples of Interacting Medicines
Increased Lipiget Exposure Strong CYP3A4 inhibitors (e.g., Clarithromycin, Itraconazole), Immunosuppressants (e.g., Cyclosporine), HIV/HCV Protease Inhibitors.
Decreased Lipiget Exposure CYP3A4 Inducers (e.g., Rifampin) if not co-administered simultaneously.

Pharmacodynamic and Risk-Based Interactions

Co-administration with certain agents may create an additive or synergistic risk for muscle toxicity, which is a key focus of regulatory information.

Risk Type Interacting Agents
Additive Muscle Risk Fibrates (e.g., Gemfibrozil), Lipid-modifying doses of Niacin (1 g/day or more), Colchicine.

Specific Restrictions and Product Interactions

Specific combinations are documented as contraindicated (not to be taken together), including certain regimens of HIV and HCV medicines. Consumption of large quantities of grapefruit juice is documented to increase Lipiget plasma concentrations and may be advised against.

Mechanism of Action

Lipiget (Atorvastatin) exerts its effect through a two-step mechanism primarily focused on modifying hepatic cholesterol homeostasis and secondarily on vascular pathway modulation.

Targeted Inhibition of Hepatic Cholesterol Production

The drug acts as a selective and competitive inhibitor of the enzyme HMG-CoA Reductase, which is the rate-limiting enzyme for the Mevalonate pathway in liver cells. This molecular interaction immediately curtails the liver's internal synthesis of cholesterol, leading to a reduction in intracellular hepatic sterol content. This action modifies early molecular steps that shape the subsequent systemic physiological outcome.

Receptor-Mediated Plasma Lipid Clearance

The internal cholesterol deficit triggers a compensatory mechanism: the liver cell increases the expression of Low-Density Lipoprotein Receptors ( LDL Receptors) on its surface. This enhanced receptor density accelerates the catabolism and removal of LDL-C (and VLDL) particles directly from the bloodstream, resulting in a lowering of systemic plasma lipid concentrations. The mechanism's efficacy is contingent upon the presence of functional LDL Receptors.

Vascular Pathway Modulation (Pleiotropic Effects)

Beyond regulating lipids, the drug's mechanism reduces the production of isoprenoid intermediates, non-sterol products of the Mevalonate pathway. By modulating these intermediates, the mechanism affects nitric oxide bioavailability and alters signaling pathways associated with vascular inflammation.

Dosage and Administration Information

How Lipiget is Used: Official Administration Guidelines

Lipiget, containing Atorvastatin, is a prescription drug administered via the oral route as a film-coated tablet. Its use is established as a long-term, chronic therapy that requires adherence to a complementary standard cholesterol-lowering diet.


Standard Dosing and Schedule

Administration Detail Official Labeled Instruction
Route & Form Oral film-coated tablet (10 mg, 20 mg, 40 mg, 80 mg strengths).
Adult Starting Dose 10 mg or 20 mg once daily; 40 mg once daily for patients requiring a reduction in LDL-C greater than 45%.
Adult Dose Range 10 mg to 80 mg once daily.
Frequency Must be taken once daily.
Timing May be taken with or without food and at any time of the day.

Procedural and Population Rules

Dosage adjustments are procedural steps to manage the chronic nature of the therapy. Adjustments in dose, if needed, should be made at intervals of 4 weeks or more following the analysis of lipid levels.

Official instructions specify use for certain populations:

  • Pediatric Patients (10–17 years with HeFH): The recommended starting dose is 10 mg once daily, with a maximum recommended dose of 20 mg once daily.
  • Renal Impairment: No dose adjustment is required for patients with impaired kidney function.

If a dose is missed, patients are advised not to take the missed dose and to resume with the next regularly scheduled dose. This procedural structure ensures the medicine is used in a standardized manner, focused on consistent daily intake and periodic medical assessment.

Recent Clinical Evidence

Research evidence / Overview of Studies for Lipiget (Atorvastatin)

The research base for Lipiget's active ingredient, Atorvastatin, is derived from extensive, regulated clinical research. This research explores whether it is associated with patterns observed in conditions characterized by systemic imbalance of fats in the blood, examining outcomes related to cardiovascular health. The findings describe group patterns observed during structured studies but do not provide individual predictions.


Evidence for use in Primary Hypercholesterolemia and Mixed Dyslipidemia

Studies were conducted using short-term and intermediate-term Randomized Controlled Trials (RCTs), primarily focusing on adults with elevated lipid levels. Research examined how the medication was associated with changes in measured biomarkers, including LDL-C (Low-Density Lipoprotein Cholesterol) and Triglycerides (TGs). Studies reported patterns associated with changes in measured levels of LDL-C and Triglycerides across various dosages compared to controls. The observed change in LDL-C was associated with the studied dosage. Long-term outcomes related to the maintenance of these specific lipid targets beyond the intermediate-term study durations are not uniformly detailed across all publications.


Research on Cardiovascular Event Reduction (Prevention)

Studies in Adults Without Existing Heart Disease (Primary Prevention)

Large-scale, long-term research was conducted on adults who did not have established heart disease but were identified as having multiple cardiovascular risk factors. These studies monitored the incidence of outcomes describing episodic or acute changes, specifically tracking the occurrence of fatal or non-fatal Myocardial Infarction (MI) and Stroke over several years. Reports described observed event rates across the groups being compared.

Studies in Adults with Existing Heart Disease (Secondary Prevention)

Research focused on adults who had experienced a prior cardiovascular event. The studies explored outcomes related to physical discomfort and physiological strain, monitoring the incidence of acute events like non-fatal MI and Stroke, as well as Revascularization Procedures. Trial reports described patterns observed, indicating that the observed rate of events was different between the study groups.


Evidence in Specific Patient Populations

Research has also been conducted on specific groups, including pediatric patients diagnosed with Heterozygous Familial Hypercholesterolemia (HeFH) and adults with certain comorbid conditions like Type 2 Diabetes Mellitus. Findings indicate patterns of measured biomarker shifts were observed in these specific patient groups. However, the sample sizes for these groups were more modest compared to the primary adult cohorts, and long-term cardiovascular outcome data—specifically tracking MACE in the pediatric subgroup—remains insufficient or limited.


Key Limitations and Areas for Further Research

Evidence is limited or lacking for patients with certain specific, rare lipid disorders, such as Fredrickson Types I and V dyslipidemias. While the volume of research exploring overall cardiovascular outcomes is extensive, follow-up durations were limited in some early trials. Comparative evidence against newer or non-statin therapies in certain subgroups may be lacking, and long-term effects on less common outcomes are not fully established. Research is ongoing to provide further insight into these areas.

Key Studies & References

  1. ATORVASTATIN CALCIUM tablet, film coated (DailyMed/FDA Prescribing Information)

Frequently Asked Questions (FAQ)

Common questions about Lipiget (FAQ)

Q: How quickly does Lipiget start to work?

According to the official product information, the maximum effect on lowering lipid levels is generally achieved within four weeks of starting treatment. A significant effect on lipid levels is generally observed within the first two weeks. The concentration of the medicine in the bloodstream typically reaches its highest point within one to two hours after you take your dose.

Q: Can Lipiget be used for reasons other than cholesterol?

Official regulatory documents state that Lipiget is formally indicated only for the management of lipid disorders and for reducing the associated cardiovascular risk. The official label does not describe official use for other specific medical conditions.

Q: Is it normal to feel tired when first starting Lipiget?

Fatigue, or feeling tired, is listed in regulatory documents as an uncommon side effect, meaning it is occasionally reported by patients. This is not listed as one of the most common side effects documented in the safety profile.

Q: Are there any common over-the-counter medicines that interact with Lipiget?

Official documents advise caution regarding certain over-the-counter (OTC) products. Medicines that affect stomach acidity, such as common antacids, may temporarily decrease the concentration of Lipiget in the blood.

Q: Can I drink alcohol while I am taking Lipiget?

Regulatory texts advise using caution regarding alcohol consumption while taking Lipiget. This is particularly noted for patients who consume substantial quantities of alcohol, as it may increase the potential for liver-related effects. Official labeling notes that patients who consume substantial quantities of alcohol should use caution or avoid consumption.

Q: Does Lipiget cause muscle pain in a lot of people?

Muscle and joint issues are noted in the safety profile. General joint pain (arthralgia) is listed as a common side effect that may affect up to 1 in 10 people. General muscle pain (myalgia) is also described in official documents as a frequently observed effect reported after the medicine was released to the market.

Q: Is Lipiget known to cause any long-term side effects?

Official regulatory information mentions the potential for certain effects to be associated with long-term use. For example, some studies have noted the observed development of diabetes mellitus in some patients using this type of medication over several years. The safety information also notes the importance of monitoring for rare, serious liver and muscle effects over time.

Q: What foods or supplements should be avoided with Lipiget?

Regulatory documents advise against consuming large quantities of grapefruit juice (more than 1.2 litres per day), as this can increase the concentration of the drug in your system. Additionally, taking high doses of the supplement Niacin (above 1 gram per day) alongside Lipiget is noted to increase the risk of muscle-related issues.

Q: Why is Lipiget sometimes prescribed with other medications?

Official regulatory documentation includes information on the co-administration of Lipiget with other lipid-modifying agents. These combinations, which may include medicines like cholestyramine or ezetimibe, are often studied and used as part of an overall treatment strategy to reach specific lipid goals.

Q: Do certain age groups react differently to Lipiget?

Official documents specify that certain age groups have different risk factors associated with this drug. For example, older age (65 years and above) is described as a factor that may increase the potential risk of developing muscle problems, such as myopathy or rhabdomyolysis.

Q: What does 'contraindication' mean regarding Lipiget?

The term contraindication in official medical language means that a medicine must not be used by a patient. For Lipiget, this is due to a specific pre-existing condition, like active liver disease or pregnancy, where the risks of taking the medication are too high.

Q: Are there any reported interactions between Lipiget and herbal remedies?

Official regulatory labels specifically warn about products containing the herbal remedy St. John's Wort. This is because St. John's Wort can reduce the level of Lipiget in the blood, which may decrease its effectiveness.

Q: How does Lipiget compare to other similar cholesterol medicines regarding its basic function?

Lipiget is classified as a statin, which works by selectively blocking the liver enzyme HMG-CoA reductase. This is its core function, which differs from the mechanisms of other classes of lipid-modifying drugs. For example, some other medications work by blocking cholesterol absorption or increasing its removal from the bloodstream.

Q: Does Lipiget require routine blood tests?

Official instructions state that liver function tests are typically performed by a healthcare professional prior to starting treatment. These tests are generally performed periodically after starting therapy to check for changes in liver enzymes, as this is a key safety consideration noted in the regulatory documents.

Q: Is Lipiget used to lower LDL or raise HDL, or both?

According to the official product information, the drug is used to reduce levels of total cholesterol, LDL-C (Low-Density Lipoprotein Cholesterol), and triglycerides. It is also described as producing variable increases in HDL-C (High-Density Lipoprotein Cholesterol).

Q: How long after starting Lipiget do people usually see changes in lab results?

Official documents indicate that changes in lipid levels are typically assessed in a clinical setting at intervals of four weeks or more after therapy is started or a dosage change is made. This period allows time for the medication to reach its maximum therapeutic effect before the next assessment.

Q: Are there any mental or cognitive side effects associated with Lipiget?

Regulatory documents report instances of certain cognitive effects, such as memory impairment and confusion, in postmarketing surveillance. These are generally noted as rare or uncommon effects.

Q: What are the signs of a serious side effect from Lipiget?

Serious side effects may be indicated by certain physical changes. These can include unexplained muscle pain or weakness, fever, dark-colored urine, or signs of liver problems such as the yellowing of the skin or eyes (jaundice).

Q: What is the meaning of the warning about muscle problems with Lipiget?

The warning about muscle problems refers to the risk of conditions like myopathy (muscle disease) and the more severe, rare condition called rhabdomyolysis. Rhabdomyolysis involves the severe breakdown of muscle tissue and can potentially lead to kidney problems.

How should Lipiget be stored and disposed of?

Lipiget (atorvastatin) must be stored under controlled conditions to maintain its labeled quality and effectiveness.

Official Storage Requirements

Lipiget tablets require storage at controlled room temperature, typically between 20 C and 25 C (68 F to 77 F), with permitted excursions up to 30 C. The tablets must be protected from excessive heat, light, and moisture. To achieve this, the medication must be kept in its original container and the lid must remain tightly closed.

Child Safety and Disposal

As with all medicines, Lipiget must be stored out of the sight and reach of children.

Regarding disposal, regulatory guidance states that unused or expired tablets should not be flushed down the toilet or poured into a drain. The preferred disposal method is using an official drug take-back program. If this is unavailable, follow the official instructions for sealing the medication in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lipiget found in:

A-Z Index: